0000899243-19-001157.txt : 20190114 0000899243-19-001157.hdr.sgml : 20190114 20190114210914 ACCESSION NUMBER: 0000899243-19-001157 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181112 FILED AS OF DATE: 20190114 DATE AS OF CHANGE: 20190114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nussbaum Robert L CENTRAL INDEX KEY: 0001640322 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36847 FILM NUMBER: 19526083 MAIL ADDRESS: STREET 1: 458 BRANNAN STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Invitae Corp CENTRAL INDEX KEY: 0001501134 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 271701898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1400 16TH STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94103 BUSINESS PHONE: (415) 374-7782 MAIL ADDRESS: STREET 1: 1400 16TH STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94103 FORMER COMPANY: FORMER CONFORMED NAME: InVitae Corp DATE OF NAME CHANGE: 20121105 FORMER COMPANY: FORMER CONFORMED NAME: Locus Development Inc DATE OF NAME CHANGE: 20100910 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2018-11-12 2018-11-14 0 0001501134 Invitae Corp NVTA 0001640322 Nussbaum Robert L C/O INVITAE CORPORATION 1400 16TH STREET SAN FRANCISCO CA 94103 0 1 0 0 Chief Medical Officer Common Stock 2018-11-12 4 S 0 8244 13.0036 D 171191 D Common Stock 2018-11-12 4 S 0 2200 13.5282 D 168991 D These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 10, 2018. The transaction code was incorrectly reported and transactions not within a one dollar price range were inadvertently aggregated on the reporting person's original Form 4. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Represents weighted average sale price. Actual sale prices ranged from $12.40 to $13.38. Includes an aggregate of 164,235 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Represents weighted average sale price. Actual sale prices ranged from $13.40 to $13.66. /s/ Patty Dumond, Attorney-in-Fact 2019-01-14